Optiscan Imaging Limited announced the appointment of Brendan Fafiani to the role of Chief Operating Officer. Effective 6 November 2023, Brendan will assume responsibility for Optiscan's operations at its Melbourne headquarters, leading the development of the Company's operational planning and overseeing its commercialisation strategy encompassing sales and marketing, as well as managing personnel, and customer and development efforts. Optiscan CEO, Dr Camile Farah, will continue to focus on key investor relations, stakeholder engagement initiatives, and the US expansion plan. Brendan joins Optiscan from Cyban Pty Ltd, where, as the Chief Executive Officer he led the initial
commercialisation of a pioneering non-invasive Brain Oxygen and Intracranial Pressure monitor. Prior to this, as Vice President of Product and General Manager at Global Kinetics, Brendan led the product development of a novel Parkinson's disease monitor through regulatory clearance and launch into the US, Europe, and APAC. Prior to relocating to Australia, as Associate Director Operations within Merck KGaA's Medical Device Global Business Franchise, headquartered in Switzerland, he was responsible for the lifecycle management of a large portfolio of device and digital technologies. Brendan brings a wealth of expertise in the introduction of new technologies into existing treatment pathways, both in start-ups undergoing rapid growth and large multinational corporations, across neurodegenerative and cardiometabolic diseases, endocrinology and acquired brain injury fields.